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Abstract: BACKGROUND ARN-509 (Apalutamide) is a unique androgen receptor (AR) antagonist for
the treatment of castration-resistant (CR) prostate cancer (PC). It inhibits AR nuclear translocation,
DNA binding and transcription of AR gene targets. As dysregulation of autophagy has been detected
in PC, the targeting of autophagy is a potential approach to overcome early therapeutic resistance.
Therefore, we investigated the characteristics of autophagic response to ARN-509 treatment and evaluated
the potential effect of a combination with autophagy inhibition. METHODS Human prostate cancer
cells (LNCaP) were cultivated in a steroid-free medium. Cells were treated with ARN-509 (50 µM)
alone or in combination with the autophagy inhibitors 3-methyladenine (3MA, 5 mM) or chloroquine
(Chl, 20 µM) or with ATG5 siRNA knock-down. Cell viability and apoptosis were measured by flow
cytometry and fluorescence microscopy. Autophagy was monitored by immunohistochemistry, AUTOdot
and immunoblotting (WES). RESULTS Treatment with ARN-509 led to cell death of up to 37% with
50 µM and 60% with 100 µM by day 7. The combination of 50 µM ARN-509 with autophagy inhibitors
produced a further increase in cell death by day 7. Immunostaining results showed that ARN-509 induced
autophagy in LNCaP cells as evidenced by elevated levels of ATG5, Beclin 1 and LC3 punctuation and
by an increase in the LC3-II band detected by WES. Autophagic flux was restored by the treatment
of cells with Chl, intensifying the LC3-II band. These findings were further supported by an enhanced
autophagosome punctuation observed by Autodot staining. CONCLUSIONS These data demonstrate
that treatment with ARN-509 leads to increased autophagy levels in LNCaP cells. Furthermore, in
combination with autophagy inhibitors, ARN-509 provided a significantly elevated antitumor effect, thus
providing a new therapeutic approach potentially translatable to patients.
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Highlights 
• Autophagy represents an important resistance mechanism to the novel drug 
Apalutamide.  
• Blocking of autophagy significantly impairs the survival of prostate cancer cell 
in vitro 
• Combination of autophagy inhibitors with Apalutamide has a significant 
inhibitory effect on LNCaP cells.   
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Abstract (350 words)  
Background: ARN-509 (Apalutamide) is a unique androgen receptor (AR) antagonist for the 
treatment of castration-resistant (CR) prostate cancer (PC). It inhibits AR nuclear translocation, 
DNA binding and transcription of AR gene targets. As dysregulation of autophagy has been 
detected in PC, the targeting of autophagy is a potential approach to overcome early therapeutic 
resistance. Therefore, we investigated the characteristics of autophagic response to ARN-509 
treatment and evaluated the potential effect of a combination with autophagy inhibition. 
Methods: Human prostate cancer cells (LNCaP) were cultivated in a steroid-free medium. Cells 
were treated with ARN-509 (50 µM) alone or in combination with the autophagy inhibitors 3-
methyladenine (3MA, 5 mM) or chloroquine (Chl, 20 µM) or with ATG5 siRNA knock-down. 
Cell viability and apoptosis were measured by flow cytometry and fluorescence microscopy. 
Autophagy was monitored by immunohistochemistry, AUTOdot and immunoblotting (WES). 
Results: Treatment with ARN-509 led to cell death of up to 37% with 50 µM and 60% with 
100 µM by day 7. The combination of 50 µM ARN-509 with autophagy inhibitors produced a 
further increase in cell death by day 7. Immunostaining results showed that ARN-509 induced 
autophagy in LNCaP cells as evidenced by elevated levels of ATG5, Beclin 1 and LC3 
punctuation and by an increase in the LC3-II band detected by WES. Autophagic flux was 
restored by the treatment of cells with Chl, intensifying the LC3-II band. These findings were 
further supported by an enhanced autophagosome punctuation observed by Autodot staining. 
Conclusions: This data demonstrates that treatment with ARN-509 leads to increased 
autophagy levels in LNCaP cells. Furthermore, in combination with autophagy inhibitors, 
ARN-509 provided a significantly elevated antitumor effect, thus providing a new therapeutic 
approach potentially translatable to patients. 




1. Introduction  
The standard first-line therapy for patients suffering from metastatic prostate cancer (PC) is 
androgen-deprivation with luteinizing hormone-releasing hormone agonists or antagonists. 
However, after a period of tumor response, nearly all men progress to castration-resistant 
prostate cancer (CRPC), which has a high mortality rate1. Additional blocking of the androgen 
receptor (AR) axis by second line agents including Abiraterone acetate and Enzalutamide has 
proven good antitumor effects in patients with advanced CRPC 2,3. However, not all patients 
respond to the therapy, and among those who do, the strength and stability of response can be 
limited. Apalutamide (ARN-509) is a unique, competitive AR inhibitor, specifically developed 
for the treatment of CRPC. This novel compound inhibits AR nuclear translocation, DNA 
binding and transcription of AR gene targets 4. To address PC, we previously already 
investigated the role of autophagy, a cellular self-digestive process that is essential at basal level 
to ensure homeostasis by the controlled degradation of cellular contents 5. In addition to an 
upregulation of autophagy proteins in men with advanced PC, we also provided evidence that 
enforced downregulation of autophagy accelerates cell death and increases the efficacy of anti-
cancer drugs such as EPI-001 and Abiraterone in prostate cancer cell lines6,7 8. Given the 
promising antitumor effect of ARN-509 in the treatment of advanced PC and the role of 
autophagy as a resistance mechanism against established PC therapy 9, we aimed to investigate 
the autophagic response to treatment with ARN-509. Furthermore, we explored the potentially 
enhanced therapeutic effects of a combination treatment of ARN-509 with autophagy inhibitors 




2. Materials and Methods 
Detailed experimental procedures are provided in supplementary and available online. 
2.1 Cell culture 
The PC cell line LNCaP (CRL-1740, ATCC, Manassas, USA) was cultivated in RPMI (Life 
Technologies, ThermoFisher SCIENTIFIC, Waltham, MA, USA) supplemented with 10% 
FBS and 1% penicillin/streptomycin and incubated at 37°C with 5% CO2. Medium was 
changed twice a week.  
Autophagy inhibition and ARN-509 treatment  
To mimic androgen deprivation, LNCaP cells were counted and cultured in a steroid-free RPMI  
medium without phenol red (Life Technologies, Waltham, MA, USA) with 5% charcoal filtered 
FBS (F6765, Sigma Aldrich, Buchs, Switzerland) for one day. After one day cells were treated 
either with ARN-509 (10, 25, 50 and 100 µM, Janssen Pharmaceutica NV, Belgium), the 
autophagy inhibitor 3-methyladenine 10 (3MA, 5 mM, Selleckchem, Luzern, Switzerland), 
chloroquine (Chl, 20 µM, Sigma Aldrich) or rapamycin (1-2 µM, Selleckchem). For 
combination treatments, cells were treated with a mixture of ARN-509 and 3MA or ARN-509 







2.1 Dose-dependent effect of ARN-509 in LNCaP cells  
In order to investigate the role of autophagy upon anticancer drug treatment, we studied the 
effect of ARN-509 at sub-lethal concentrations and assessed the level of cell proliferation in 
the androgen sensitive prostate cancer cell line LNCaP in different dose and time points. Cells 
were examined after treatment with different concentrations of ARN-509 in androgen-depleted 
medium (charcoal filtered) on days 1, 3 and 7. Reduction in cell proliferation was already 
observed at day 1, when cells were treated with 10 µM (100 ± 2.9, SEM), 25 µM (99 ± 3.5), 50 
µM (86 ± 1.7), 75 µM (84.9 ± 2.6) and 100 µM (86 ± 1.9) of ARN-509 compared to DMSO 
treated control cells (100%), with a significance observed with doses of 50 µM and above 
(Figure 1A). The same reduction was observed on day 3 with ARN-509 concentrations of 10 
µM (86 ± 3.0), 25 µM (85.26 ± 5.0), 50 µM (73 ± 9.5), 75 µM (69.7 ± 2.7) and 100 µM (63.7 
± 2.1) compared to DMSO control. On day 7, the ARN-509 treatment with 10 µM (88.4 ± 9), 
25 µM (79.46 ± 9), 50 µM (62.64 ± 2.3), 75 µM (48 ± 3.5) and 100 µM (39 ± 2.9) led to further 
reduction as compared to control. Taken together, a significant cell death in LNCaP cells was 
induced only in higher concentrations (50, 75 and 100 µM) ARN-509 at all time points as 
compared to vehicle control (Figure 1A) with a more pronounced effect observed on days 3 and 
7. For all subsequent experiments, we proceeded with the efficient dose of 50 µM ARN-509.  
2.2 Treatment with anti-cancer drug ARN-509 induces autophagy in LNCaP cells  
To define the role of autophagy in the survival of cancer cells and whether autophagy inhibition 
can enhance the cell killing effect of ARN-509, LNCaP cells were treated with 50 µM ARN-
509 alone or in combination with the autophagy inhibitors 20 µM Chl, or 5 mM 3MA. 
Importantly, cells treated with ARN-509 plus 3MA (45.68 ± 8.0,) or ARN-509 plus Chl (37.7 
± 0.7) showed significantly reduced cell proliferation compared to ARN-509 treated cells only 
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(75.8 ± 6.1, SEM) and DMSO control (97.1 ± 5.6), demonstrating that autophagy plays a part 
in the cell proliferation mechanism in response to therapy (Figure 1B). As autophagosome 
formation is one of the main characteristic of autophagy, we explored the link between 
autophagy related protein expression and autophagosome formation in LNCaP cells upon 
treatment with ARN-509 and combinations. As assessed by immunofluorescence, both the 
untreated and DMSO treated cell controls showed low basal expression levels of ATG5, Beclin 
1 and weak diffused LC3 staining (Figure 2). ARN-509 treated cells showed an increased cell 
size, an induced cytoplasmic expression for ATG5 (Figure 2, upper panel) and Beclin 1 (lower 
panel), and a punctuated pattern for LC3, confirming the accumulation of autophagosomes 
upon treatment at day 7. The cells treated with a combination of ARN-509 and 5 mM 3MA, 
showed a reduced expression of ATG5 and Beclin 1 and no LC3 punctuations with disrupted 
cell morphology and reduction of cell growth (Figure 2). Moreover, Chl-treated cells in 
combination with ARN-509 showed accumulation of LC3 protein indicating a Chl-induced 
accumulation of autophagic vacuoles (Figure 2).  
Autophagosome formation was also monitored by AUTOdot fluorescence staining (Figure 3). 
The LNCaP cells treated with ARN-509 revealed significantly increased autophagosome 
formation compared to untreated cells or DMSO controls, as identified by enhanced green 
punctuation in the cells. In addition, ARN-509 treated cells showed the characteristic features 
of autophagy, such as increased cell size and autophagic vacuoles, cells treated with autophagy 
inducer, rapamycin served as positive control (Figure 3A and S1). Moreover, cells treated with 
the combination of ARN-509 and 3MA or Chl showed a significantly increased cell death and 
a reduced cell number compared to ARN-509 treated cells only. However, Chl-treated cells 
exhibited a Chl-induced accumulation of autophagic vacuoles in the remaining 
autophagosomes shown by enhanced green punctuation. Quantification of AUTOdot positive 
cells indicated that ARN-509 treated cells had a high green punctuation content similar to the 
one observed by LC3 staining (Figure 3B) which could be blocked in combination conditions. 
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2.3 Combined treatment of ARN-509 with autophagy inhibitors induces apoptosis in 
LNCaP cells 
We then explored the effect of pharmacological inhibition of autophagy on cell survival in 
LNCaP cells. Therefore, LNCaP cells were treated with 50 μM ARN-509 alone and in 
combination with the autophagy inhibitors 20 μM Chl or 5 mM 3MA, and cell viability was 
measured using ethidium bromide and detected by flow cytometry. An increased rate of cell 
death was detected in all the experimental conditions compared to DMSO-control on days 1 
and 3. However, the most prominent cell death was observed on day 7. An increased rate of cell 
death was observed in cells treated with ARN-509 (29.97 % ± 1.9), 3MA (46.4 % ± 0.7), and 
Chl (35.4 % ± 0.38) compared to DMSO-control (27.02 % ± 3.1). Prominently, a combination 
treatment of ARN-509 + Chl (50.3%± 4.9, P = 0.0006) and ARN-509 + 3MA (53.2 %± 1.2, P 
= 0.0001) resulted in a significantly reduced cell viability compared to ARN-509 alone. 
Increased cell death was also linked to a significant increase in apoptosis as measured by 
Annexin V assay showing the phosphatidylinositol redistribution in cells upon different 
treatments. In line with the cell death results, a significant increase in apoptosis was observed 
in the combination of ARN-509 + Chl (8.653 ± 0.16, P < 0.0001) compared to single ARN-509 
(2.487 ± 0.22) or Chl (2.803 ± 0.42) treatments on day 7. In contrast, single 3MA (2.47 ± 0.88) 
treatment as well as the combination ARN-509 + 3MA (3.12 ± 0.03) did not induce apoptotic 
cell death, indicating an induction of cell death via alternative pathways (Figure 4A-B). In 
parallel, we analyzed the protein expression of ATG5, Beclin 1, LC3 and P62 by 
immunoblotting. ARN-509 treatment increased the key autophagy markers ATG5 and Beclin 
1 (Figure S2) and reduced P62 expression compared to DMSO-treated control (vehicle) (Figure 
4C). These results were also confirmed by the conversion of cytosolic LC3-I to membrane-
bound LC3-II detected upon ARN-509 treatment compared to control. Similarly, a combination 




2.4 siRNA‐mediated inhibition of autophagy induces apoptosis in LNCaP cells 
ATG5 has been shown to be essential for the autophagy process. Therefore, to specifically 
reduce autophagic activity, we blocked the expression of ATG5 by using ATG5 short interfering 
RNA (siRNA, Figure. 5). Similar to pharmacological treatments, we tested the influence of 
ATG5 suppression on LNCaP cells and examined the percentage of cell death and 
apoptosis/necrosis in the cells. Cell death was higher in 30 nM ATG5 siRNA treated cells 
compared to control (113% ± 4.2, SD) and significantly higher upon combination treatment 
with ARN-509 50 µM (139.2 % ± 1.6, p <0.0001) (Figure 5A). Moreover, ATG5-suppressed 
LNCaP cells showed a significantly increased sensitivity towards the effect of ARN-509 (180.5 
% ± 9.2, p <0.0001) compared to ARN-509 treatment alone (Figure 5A). Similarly, in 
comparison to untreated cells and siRNA treated cells (150.3 % ± 16.11, SEM), an increased 
susceptibility to apoptosis was detected in cells treated with ARN-509 (232.2% ± 24.45, p 
<0.0001). This effect was significantly enhanced when cells were treated with the combination 
of ARN-509 plus ATG5 siRNA (355.0 % ± 20.6, p <0.0001). No changes were observed in 
propidium iodide treated cells. The enhanced blockage of ATG5 protein expression via 





In this study, we describe for the first time that Apalutamide (ARN-509) treatment induces pro-
survival autophagy in AR expressing prostate cancer cells (LNCaP). Furthermore, we 
demonstrate that a combination of ARN-509 with autophagy inhibitors significantly increases 
the antitumor effect in vitro. ARN-509 is a novel competitive inhibitor of the AR and is 
currently being investigated for the treatment of prostate cancer in different clinical settings. It 
binds irreversibly to the ligand binding pocket of the AR and shows a 7-10 fold greater affinity 
to the AR than Bicalutamide. Furthermore, a maximal antitumor effect has been demonstrated 
at up to 4-fold lower concentrations in the central nervous system compared to Enzalutamide, 
suggesting a lower seizurogenic potential. In mice xenograft models, ARN-509 showed a dose-
dependent tumor regression that is greater than the one achieved with Bicalutamide or 
Enzalutamide 4. In addition, the safety and efficacy of the compound has been proven in a first-
in-human phase I study in metastatic CRPC 11, while a phase II study reported a significant 
antitumor activity in patients with non-metastatic CRPC 12. Recently, the results of the 
SPARTAN trial led to the approval of Apalutamide (ErleadaTM) for the treatment of non-
metastatic CRPC 13. Clinical benefits were also shown in Abiraterone-naïve and Abiraterone-
treated patients with metastatic CRPC 14. Ongoing clinical trials are further investigating the 
role of ARN-509 in different cancer stages 15.  
However, in advanced prostate cancer, cells are capable of adapting and surviving the effects 
of therapies through different mechanisms 16,17. In 2013, Joseph et al. described an AR point 
mutation (AR F877L, formerly AR F876L) as one possible mechanism of acquired resistance 
to ARN-509 and Enzalutamide 18. Interestingly, Rathkopf et al. could not confirm AR point 
mutation F877L as contributor to de novo or acquired resistance to ARN-509 in a prospective 
patient cohort 19. Another specific mechanism of survival is upregulation of autophagy 6,20 21. 
Therefore, targeting autophagy is a potential approach to overcome early therapeutic resistance.  
10 
 
Autophagy is a cellular recycling process that is designed to degrade long-lived proteins and 
organelles in order to maintain homeostasis in the cells 22. Several proteins are involved in the 
autophagy process. Some main elements that are involved in autophagosome formation are 
ATG12-ATG5 and the microtubule-associated protein 1 light chain 3 (LC3)-
phosphatidylethanolamine (PE) systems 22. Here, we report that ATG5, a protein required for 
autophagosome formation, is upregulated upon ARN-509 treatment and promotes cellular 
survival in LNCaP cells. In parallel, we observed an elevated Beclin 1 expression with increased 
levels of LC3. This confirms the novel role of these proteins in mediating protective autophagy 
and apoptosis in prostate cancer cells. Although WES quantification showed no significance, 
our results were further confirmed by cell death, apoptosis and autophagy down regulation 
assays. In addition, we show inhibition of autophagy in cells treated with ARN-509, either 
pharmacologically or by siRNA knock down of the ATG5 gene. The use of ATG5 siRNA 
sensitizes LNCaP cells to ARN-509 and induces apoptosis. We have previously shown that the 
inhibition of autophagy enhances cell-killing effects of Abiraterone acetate in LNCaP cells 7. 
In addition, we have shown that combined N-terminal AR binding and autophagy inhibition 
increases the antitumor effect in Enzalutamide-sensitive and -resistant prostate cancer cells 6. 
In line with our findings, growing evidence suggests that autophagy inhibition increases 
cytotoxicity in combination with several anticancer drugs in preclinical models 23,24. Several 
compounds can inhibit autophagy via different pathways at various stages. We have used two 
autophagy inhibitors to block the autophagy cascade at different stages. 3-methyladenine is a 
well-established and widely used autophagy inhibitor for in vitro experiments 25. Based on its 
inhibitory effect on PI3K activity 26 it can inhibit at earlier stage of autophagosome formation.  
Chloroquine is a well-established, Food and Drug Administration (FDA) -approved autophagy 
inhibitor, which has been used in the treatment and prevention of malaria 27. Chloroquine blocks 
autophagy at later stages in the process by interfering with lysosome acidification and by 
impairing autophagosome degradation 27. The general idea of using anticancer therapy in 
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combination with autophagy inhibitors for prostate cancer treatment is currently being 
investigated in clinical trials such as “Akt inhibitor MK2206 and hydroxychloroquine in 
treating patients with advanced solid tumors or prostate cancer” (Phase I, Identifier: 
NCT01480154). However, the PANDORA phase II trial could not report a superior efficacy of 
a combined therapy of docetaxel with autophagy inhibition over docetaxel treatment alone in 
patients with CRPC 28. In cells treated with either 3MA alone or in combination with 50 µM 
ARN-509, cell death has been induced without any effect on the apoptotic machinery. This 
form of cell death is dependent on autophagy proteins that are involved in the formation of 
autophagosomes 29. Conversely, a significant apoptotic cell death was observed when the cells 
were treated with the combination of ARN-509 and Chl as compared to single ARN-509 or Chl 
treatments.  
In addition, our results and the used concentrations are in line with a recent study by 
Koukourakis et al. where they compared the effect of 50 µM ARN-509 and 100 µM ARN-509 
to Bicalutamide on androgen receptor expression and kinetics in 22RV1 cells. In this study, 
ARN-509 showed a stronger antiproliferative effect compared to Bicalutamide, which was 
more prominent in the androgen receptor expressing cell line 22Rv1. A completely suppressed 
cell proliferation was observed at a concentration of 100 µM ARN-509 30. In clinical phase I 
trial Rathkopf et al. performed a dose escalation to 480 mg daily and did not identify a 
maximum tolerated dose 11. In clinical phase II and phase III trials 240 mg daily were used 13,31. 
Calculated doses for a 70kg patient used in our experiments are 7 x higher than doses used in 
phase II and phase III trials and 3.4 x higher than the maximum tested dose. However, a direct 
comparison of concentrations used in vitro to concentrations used in vivo or in patients is not 




In conclusion, our data indicates that autophagy represents an important resistance mechanism 
to the novel drug ARN-509. Pharmacological or genetic blocking of autophagy significantly 
impairs the survival of prostate cancer cell in vitro, implying a therapeutic potential of 
autophagy inhibitors in combination with AR inhibitors. However, pre-clinical studies 
investigating the association between ARN-509 therapy and chloroquine are clearly required to 
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Dose-dependent cell proliferation assay of LNCaP cells in response to ARN-50. A) LNCaP 
cells were treated with different concentration of ARN-509 5, 10, 25, 50, 75 and 100 µM for 1, 
3 and 7 days. B) Cell proliferation in response to combined ARN-509 and autophagy inhibition. 
LNCaP were cultured in the presence of 50 μM ARN-509, 20 μM Chl, 5mM 3MA and  
combinations of 50 μM ARN-509 + 20 μM Chl and 50 μM ARN-509 + 5mM 3MA. Cell 
proliferation was assessed using WST-1 assay, absorbance was measured at 450 nm daily. Data 
represent mean ± SEM (n = 4), in triplicates. All treatment groups were compared to untreated 
control (corresponding day defined as 100%). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 
0.0001 showing percentage of growth relative to control. 
Figure 2: 
Upregulation of ATG5, Beclin 1 and LC3 in ARN-509 treated cells. Confocal images of LNCaP 
cells treated cells with 50 μM ARN-509, 5 mM 3MA, 20 μM Chl or a combination of ARN-
509 and 3MA or ARN-509 and Chl, stained with anti-ATG5, Beclin 1 and LC3 antibodies. 
Immunofluorescence staining indicates expression of autophagy lineage specific markers 
ATG5 (upper panel, green color) or Beclin 1 (lower panel, green), and LC3 expression (red). 
The LC3 punctuation indicates autophagosome formation and high autophagic activity in ARN-
509 treated cells. Samples were detected using Cy3 (red) conjugated secondary antibody or 
FITC (green) and DAPI (blue, 4′,6-diamidino-2-phenylindole). 
Figure 3: 
A) LNCaP cells treated with ARN-509 for 7 days  and stained with AUTOdot. Significant 
increase in autophagosomes and punctuation was observed in cells treated with ARN-509. 
Cells treated with ARN-509 in combination with 3MA or Chl showed significant reduction 
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compared to ARN-509 treated cells only. Scale bars: 50 μm B) Graph indicates quantitative 
measurement of fluorescent intensity using Image J software. *p < 0.0001. (N = 6 per 
condition of microscopic field images).  
Figure 4: 
Effect of ARN-509 and autophagy inhibition on cells viability, apoptosis, and protein 
expression in response to combined ARN-509 and autophagy inhibition. LNCaP cells were 
cultured in the presence of 50 μM ARN-509, 20 μM Chl, 5mM 3MA and of combinations of 
50 μM ARN-509 + 20 μM Chl and 50 μM ARN-509 + 5mM 3MA. Cell viability was assessed 
using ethidium bromide and measured by FACS (A). B) Apoptosis was measured by flow 
cytometry using Annexin V staining. Cells were treated with the above indicated compounds 
and combinations. Data is shown as mean with standard error of the mean (±SEM) of 3-6 
independent experiments. All the treatment groups were compared to vehicle control (0.1% 
DMSO) at day 7. *P < 0.05, **P < 0.01, ***P<0.001. C) Effects of 50 μM ARN-509, 20 μM 
Chl, 5mM 3MA and their combinations on ATG5, Beclin 1, LC3, and p62 protein levels in both 
cell lines analyzed by immunoblotting. 
Figure 5: 
Increasing cell death by dual action of silencing ATG5 and ARN-509 treatment. LNCaP cells 
were treated with 30 nM ATG5 siRNA, 50 μM ARN-509, 50 μM EPI + 30 nM ATG5 siRNA 
and following assays were performed after 7 days of growth upon treatments. A) Cell death 
was measured using ethidium bromide and analysed by FACS. Values are mean ± SEM of at 
least three independent experiments. B) Cell apoptosis assay. Annexin V/PI staining of 
untreated and treated LNCaP cells. Results are presented as percentage of positive cells 
compared to control. The data represent the mean ± SEM (n = 3). **p < 0.001, ***p < 0.0001. 




Figure S1:  
LNCaP cells treated with ARN-509 or Rapamycin for 7 days and stained with AUTOdot. 
Significant increase in autophagosomes and punctuation was observed in cells treated with 
both ARN-509 and rapamycin. Cells treated with ARN-509 showed autophagic vacuole 
formation, which is a typical feature of autophagy. Scale bars: 50 μm. 
Figure S2: WES analysis.  Quantification of 50 μM ARN-509, 20 μM Chl, 5mM 3MA and their 
combinations on ATG5 and Beclin 1 protein expression. The data represent the mean ± SEM 
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2. Supplementary Materials and Methods 
2.1 Cell culture 
The PC cell line LNCaP (CRL-1740, ATCC, Manassas, USA) was cultivated in RPMI (Life 
Technologies, ThermoFisher SCIENTIFIC, Waltham, MA, USA) supplemented with 10% 
FBS and 1% penicillin/streptomycin and incubated at 37°C with 5% CO2. Medium was 
changed twice a week.  
Autophagy inhibition and ARN-509 treatment  
To mimic androgen deprivation, LNCaP cells were counted and cultured in a steroid-free RPMI  
medium without phenol red (Life Technologies, Waltham, MA, USA) with 5% charcoal filtered 
FBS (F6765, Sigma Aldrich, Buchs, Switzerland) for one day. After one day cells were treated 
either with ARN-509 (10, 25, 50 and 100 µM, Janssen Pharmaceutica NV, Belgium), the 
autophagy inhibitor 3-methyladenine 1 (3MA, 5 mM, Selleckchem, Luzern, Switzerland), 
chloroquine (Chl, 20 µM, Sigma Aldrich) or rapamycin (1-2 µM, Selleckchem). For 
combination treatments, cells were treated with a mixture of ARN-509 and 3MA or ARN-509 
and Chl. The media (plus treatments) were changed on day 3. All experiments were performed 
in triplicates. ATG5 siRNA (SASI_Hs01_00173156, Sigma-Aldrich) transduction was 
performed 2,3 using N-TER Nanoparticle siRNA Transfection system (Sigma-Aldrich) 
according to the manufacturer’s’ protocol. 
2.2 WST-1 cell proliferation assays 
The cell proliferation of treated and untreated cells (control) were measured by WST-1 assay 
on day 1, 3, and 7 according to the manufacturer’s protocol (Roche Applied Science, 
Indianapolis, IN, USA). The cells were incubated with the WST-1 reagent for 3 h at 37°C, 5% 
CO2 environment and absorbance was measured at 450 nm on a microplate reader AD340 
(Beckman Coulter Inc., Brea,CA, USA). 
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2.3 Cell death assays  
Cell death was measured by ethidium bromide uptake and flow cytometric analysis (FACS, 
Becton Dickinson FACS Canto flow cytometer) 3,4. To determine whether cell death was 
apoptotic, redistribution of phosphatidylserine (PS) was assessed using Annexin V kit (BD 
Biosciences, Allschwil, Switzerland) and Propidium iodide (Sigma-Aldrich), detected by flow 
cytometry 4. Data was evaluated using FlowJo software v. 7.5 (Tree Star Inc., Ashland, Oregon, 
USA). All data was expressed as a percentage of positive cells. 
2.4 Monitoring autophagosome formation by AUTOdot staining  
Cells were seeded on Lab-Tek chamber slides (Thermo Scientific, Nunc, Switzerland) 1 day 
prior to the experiments. After treatment of cells according to the indicated stimuli, cells were 
incubated with AUTOdot (1:1000; Abgent) at 33°C for 15 min. Cells were then washed twice 
with PBS and fixed with 4% para-formaldehyde before mounting. The excitation filter of 
AUTOdot was 380 to 420 nm, and the barrier filter was 450 nm. Slides were analyzed by laser 
confocal microscope (CLSM-SP8, Leica microscope). 
2.5 Protein Simple WES Immunoblotting  
Total protein was measured with the BCA Protein Assay Kit (Thermo Scientific, Lausanne, 
Switzerland). 1 mg/ml of protein was used for the WES sample preparation using 12-230 KDa 
cartridge kit and the proteins were separated in WES with a capillary cartridge according to the 
manufacturer’s protocols (Protein Simple WES, Germany). The primary antibodies for 
autophagy specific proteins were mouse anti-ATG5 (1:100, nanoTools, Teningen, Germany), 
rabbit anti-Beclin 1 (1:50, Novus Biologicals Europe, Abingdon, United Kingdom), and mouse 
anti-LC3 (1:50, Novus Biologicals Europe); mouse anti-GAPDH (1:100, Novus Biologicals 
Europe) served as internal control. 
2.6 Immunofluorescent staining 
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Cells were cultured on Lab-Tek chamber slides in growth medium for 1 day. The next day cells 
were treated as mentioned in 2.2. The indirect immunostainings for cells were performed at 4°C 
overnight using the primary antibodies Anti- ATG5 (Sigma, 1:100) and LC3 (nanoTools, 
1:100). The slides were incubated with secondary antibodies: goat anti-rabbit FITC (Vector 
Laboratories) or Cy3-conjugated goat anti-mouse antibody (Sigma, 1:1000) at room 
temperature for 1 h. After counter-staining with DAPI (4',6-diamidino-2-phenylindole, Sigma, 
1:200) the slides were analysed with a Leica fluorescence microscope (CTR 6000). 
2.7 Statistical analysis 
All data were analysed by Student’s t-test or one-way ANOVA with Bonferroni post analysis 
(p<0.05 was considered significant). All data presented are expressed as means with 
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